LSBCF — LakeShore Biopharma Co Cashflow Statement
0.000.00%
Last trade - 00:00- $33.79m
- $88.49m
- CNY614.96m
Annual cashflow statement for LakeShore Biopharma Co, fiscal year end - March 31st, CNY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -192 | -106 | -145 | -433 | -100 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 86.5 | 21.3 | 17.9 | 164 | 62 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -187 | -125 | -92.7 | -45.8 | -115 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -247 | -174 | -182 | -295 | -121 |
| Capital Expenditures | -105 | -299 | -57 | -44.3 | -17.9 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.645 | 0.008 | 0.068 | 0 | 0.852 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -104 | -299 | -57 | -44.3 | -17 |
| Financing Cash Flow Items | — | — | 217 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 739 | 365 | 317 | 205 | -3.58 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 388 | -119 | 99.3 | -124 | -139 |